79 related articles for article (PubMed ID: 24036284)
1. Oxidative modification of serum proteins in multiple sclerosis.
Sadowska-Bartosz I; Adamczyk-Sowa M; Galiniak S; Mucha S; Pierzchala K; Bartosz G
Neurochem Int; 2013 Nov; 63(5):507-16. PubMed ID: 24036284
[TBL] [Abstract][Full Text] [Related]
2. Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment.
Adamczyk-Sowa M; Galiniak S; Żyracka E; Grzesik M; Naparło K; Sowa P; Bartosz G; Sadowska-Bartosz I
Oxid Med Cell Longev; 2017; 2017():7905148. PubMed ID: 29181127
[TBL] [Abstract][Full Text] [Related]
3. Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment.
Sadowska-Bartosz I; Adamczyk-Sowa M; Gajewska A; Bartosz G
J Neuroimmunol; 2014 Jan; 266(1-2):67-74. PubMed ID: 24290230
[TBL] [Abstract][Full Text] [Related]
4. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Festoff BW; Li C; Woodhams B; Lynch S
J Neurol Sci; 2012 Dec; 323(1-2):61-5. PubMed ID: 22967748
[TBL] [Abstract][Full Text] [Related]
5. The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF.
Ljubisavljevic S; Stojanovic I; Vojinovic S; Stojanov D; Stojanovic S; Cvetkovic T; Savic D; Pavlovic D
Neurochem Int; 2013 Jun; 62(7):988-97. PubMed ID: 23500606
[TBL] [Abstract][Full Text] [Related]
6. Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics.
Pasquali L; Pecori C; Lucchesi C; LoGerfo A; Iudice A; Siciliano G; Bonuccelli U
Clin Biochem; 2015 Jan; 48(1-2):19-23. PubMed ID: 25300461
[TBL] [Abstract][Full Text] [Related]
7. Increased advanced oxidation protein products in Behçet's disease: a new activity marker?
Yazici C; Köse K; Caliş M; DemIr M; Kirnap M; Ateş F
Br J Dermatol; 2004 Jul; 151(1):105-11. PubMed ID: 15270878
[TBL] [Abstract][Full Text] [Related]
8. Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.
Adamczyk-Sowa M; Sowa P; Mucha S; Zostawa J; Mazur B; Owczarek M; Pierzchała K
Med Sci Monit; 2016 Jul; 22():2484-91. PubMed ID: 27420299
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress, as measured by protein oxidation, is increased in primary Sjøgren's syndrome.
Norheim KB; Jonsson G; Harboe E; Hanasand M; Gøransson L; Omdal R
Free Radic Res; 2012 Feb; 46(2):141-6. PubMed ID: 22126431
[TBL] [Abstract][Full Text] [Related]
10. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.
Valli A; Suliman ME; Meert N; Vanholder R; Lindholm B; Stenvinkel P; Watanabe M; Barany P; Alvestrand A; Anderstam B
Clin Chim Acta; 2007 Apr; 379(1-2):87-94. PubMed ID: 17292872
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP
Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392
[TBL] [Abstract][Full Text] [Related]
12. The oxidation-reduction state of serum proteins in multiple sclerosis patients: effect of interferon beta-1b.
Lucas M; Bellido L; Dinca L; Solano F; Zayas MD; Izquierdo G
Neurochem Int; 1999 Apr; 34(4):287-9. PubMed ID: 10372915
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis.
Alagozlu H; Gorgul A; Bilgihan A; Tuncer C; Unal S
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):80-5. PubMed ID: 22572519
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
15. The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults.
Wykretowicz A; Adamska K; Krauze T; Guzik P; Szczepanik A; Rutkowska A; Wysoki H
Free Radic Res; 2007 Jun; 41(6):645-9. PubMed ID: 17516236
[TBL] [Abstract][Full Text] [Related]
16. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis.
Baskol G; Demir H; Baskol M; Kilic E; Ates F; Karakukcu C; Ustdal M
Cell Biochem Funct; 2006; 24(4):307-11. PubMed ID: 16142689
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
18. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
19. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study.
Stępień A; Chalimoniuk M; Lubina-Dąbrowska N; Chrapusta SJ; Galbo H; Langfort J
Neuroimmunomodulation; 2013; 20(4):213-22. PubMed ID: 23711618
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
